Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acetazolamide for Sleep Apnea Associated Hypertension
NCT02220803Phase 2
Key facts
- Status
- Completed
- Start
- Mar 2014
- Primary completion
- Aug 2016
- Countries
- 1
- Sponsor
- University of Gothenburg
- Modality
- Small Molecules
- Drugs
- acetazolamide
- Conditions
- hypertension (HTN)
01
Overview
Phase 2, randomised, open-label trial of acetazolamide in hypertension (HTN), sponsored by University of Gothenburg. Started Mar 2014; status: completed.
02
Design
- Study design
- RandomizedOpen-label
03
Who it enrols
Obese males (BMI >= 35) with moderate-to-severe obstructive sleep apnea (AHI > 15) and established hypertension (>= 160/95).
04
Registry description
This is a short term open, randomized cross over trial to explore and compare the efficacy of pharmacological carbonic anhydrase (CA) inhibition on obstructive sleep apnea (OSA) related hypertension. Patients will be randomized to receive Acetazolamide(Diamox®)(ACZ), Continuous Positive Airway Pressure (CPAP)or CPAP plus ACZ for 2 weeks. Following a 2 week wash-out period all study participants will receive the alternative treatment regimen. The total length of the study will be 10 weeks. The effects of carbonic anhydrase inhibition on blood pressure,hemodynamics and sleep apnea will be…
Beyond the preview
Go deeper on NCT02220803.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02220803.